Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Received China IND Approval of Its FXR Agonist ASC42 for Chronic Hepatitis B Indication

HANGZHOU, China and SHAOXING, China, June 7, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)...

2021-06-07 08:30 2679

Gannex Received China IND Approval of Its FXR Agonist ASC42 for NASH Indication

SHANGHAI, May 27, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX...

2021-05-27 08:30 2542

Clinical Trial Application of ASC40 Combined with Bevacizumab to Treat Patients with Recurrent Glioblastoma Accepted by China NMPA

HANGZHOU and SHAOXING, China, May 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) t...

2021-05-25 08:30 2370

Ascletis Announces Positive Phase IIa HBV Results on Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)

HANGZHOU and SHAOXING, China, May 5, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) toda...

2021-05-05 08:30 2699

Gannex Announces the First Cohort Dosed in a U.S. Clinical Study with THR-β Agonist ASC41

SHANGHAI, April 14, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HK...

2021-04-14 20:00 2658

Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021

HANGZHOU, China and SHAOXING, China, April 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672...

2021-04-12 08:30 2697

Ascletis Announced Four Clinical and Preclinical Study Abstracts of NASH and HBV Accepted as Poster Presentations by the International Liver Congress™ 2021

Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors

* Proposed Initiation of a Pivotal Phase II Trial of ASC40 in Combination with Bevacizumab in Chi...

2021-03-30 08:00 3165

Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors

FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH

* Oral FASN inhibitor ASC40 shown to meaningfully reduce liver fat with a 50% responder rate * ...

2021-03-09 08:30 6543

Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-β Agonist ASC41 for NASH

SHANGHAI, Feb. 24, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-02-25 08:30 2723

Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-β Agonist ASC41

SHANGHAI, Feb. 21, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-02-21 19:30 3397

Ascletis Joins Sagimet's US$80 Million in Crossover Financing with Premium Investors

HANGZHOU, China and SHAOXING, China, Feb. 11, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2021-02-11 22:30 10402

Gannex Announces Positive Phase I Clinical Results on Its THR-β Agonist ASC41

SHANGHAI, Jan. 11, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-01-12 08:30 2040

First Subject Dosed with Gannex's FXR Agonist ASC42 in a U.S. Phase I Trial

SHANGHAI, Dec. 28, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-12-28 08:30 3531

Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial

SHANGHAI, Dec. 22, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-12-22 19:18 2767

Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42，an FXR Agonist

SHANGHAI, Dec. 14, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-12-14 08:30 2560

Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study

HANGZHOU and SHAOXING, China, Dec. 4, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672) announc...

2020-12-04 08:00 3455

Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

SHANGHAI, Nov. 30, 2020 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2020-11-30 08:00 2720

ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China

SHANGHAI and SAN FRANCISCO, Nov. 19, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned c...

2020-11-19 08:30 2810

Change in Use of Proceeds From the Global Offering for Expansion of R&D Portfolio into Hepatitis B Clinical Cure and NASH

HANGZHOU, China and SHAOXING, China, Nov. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code...

2020-11-18 17:00 6665

Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42，an FXR Agonist

SHANGHAI, Oct. 12, 2020 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis...

2020-10-12 08:30 8260